De Faire U - Search Results

1

Coronary angiographic changes during 2 years after myocardial infarction largely undetected by repeated tomographic thallium-201 scintigraphy and not reflected by clinical symptoms.

Ericsson CG, Hamsten A, Landou C, Mesko L, Müller-Suur R, Nilsson J, De Faire U. Ericsson CG, et al. Among authors: de faire u. Eur Heart J. 1993 Jul;14(7):891-7. doi: 10.1093/eurheartj/14.7.891. Eur Heart J. 1993. PMID: 8375411

2

Minimum heart rate and coronary atherosclerosis: independent relations to global severity and rate of progression of angiographic lesions in men with myocardial infarction at a young age.

Perski A, Olsson G, Landou C, de Faire U, Theorell T, Hamsten A. Perski A, et al. Among authors: de faire u. Am Heart J. 1992 Mar;123(3):609-16. doi: 10.1016/0002-8703(92)90497-j. Am Heart J. 1992. PMID: 1539512

3

Long-term prognostic significance of M mode echocardiography in young men after myocardial infarction.

Eriksson SV, Caidahl K, Hamsten A, de Faire U, Rehnqvist N, Lindvall K. Eriksson SV, et al. Among authors: de faire u. Br Heart J. 1995 Aug;74(2):124-30. doi: 10.1136/hrt.74.2.124. Br Heart J. 1995. PMID: 7546989 Free PMC article.

4

Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients.

Ericsson CG, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U. Ericsson CG, et al. Among authors: de faire u. Lancet. 1996 Mar 30;347(9005):849-53. doi: 10.1016/s0140-6736(96)91343-4. Lancet. 1996. PMID: 8622389 Clinical Trial.

5

Secondary preventive potential of lipid-lowering drugs. The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT).

de Faire U, Ericsson CG, Grip L, Nilsson J, Svane B, Hamsten A. de Faire U, et al. Eur Heart J. 1996 Dec;17 Suppl F:37-42. doi: 10.1093/eurheartj/17.suppl_f.37. Eur Heart J. 1996. PMID: 8960446 Review.

6

Progression of coronary artery disease in young male post-infarction patients is linked to disturbances of carbohydrate and lipoprotein metabolism and to impaired fibrinolytic function.

Båvenholm P, de Faire U, Landou C, Efendic S, Nilsson J, Wiman B, Hamsten A. Båvenholm P, et al. Among authors: de faire u. Eur Heart J. 1998 Mar;19(3):402-10. doi: 10.1053/euhj.1997.0752. Eur Heart J. 1998. PMID: 9568444

7

Does diffuse coronary atherosclerosis affect the relation between coronary stenoses and uptake of thallium-201 after exercise?

Ericsson CG, Erhardt L, Hamsten A, Mesko L, Szamosi A, Zetterquist S, de Faire U. Ericsson CG, et al. Among authors: de faire u. Clin Physiol. 1992 Jul;12(4):475-85. doi: 10.1111/j.1475-097x.1992.tb00351.x. Clin Physiol. 1992. PMID: 1505169

8

Risk factors for coronary artery disease in families of young men with myocardial infarction.

Hamsten A, de Faire U. Hamsten A, et al. Among authors: de faire u. Am J Cardiol. 1987 Jan 1;59(1):14-9. doi: 10.1016/s0002-9149(87)80061-9. Am J Cardiol. 1987. PMID: 3812225

9

Comparative study of echo- and angiocardiographically determined regional left ventricular wall motion in recent myocardial infarction.

Lindvall K, Hamsten A, Landou C, Szamosi A, de Faire U. Lindvall K, et al. Among authors: de faire u. Eur Heart J. 1984 Jul;5(7):533-44. doi: 10.1093/oxfordjournals.eurheartj.a061703. Eur Heart J. 1984. PMID: 6479180

10

Design features of a five-year Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT).

de Faire U, Ericsson CG, Hamsten A, Nilsson J. de Faire U, et al. Drugs Exp Clin Res. 1995;21(3):105-24. Drugs Exp Clin Res. 1995. PMID: 7555614 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

540 results

Search Page

Filters